US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Oncotelic Therapeutics, Inc.

0.0465

-0.0005-1.17%

Volume:39.91K

Turnover:1.92K

Market Cap:20.53M

PE:- -

High:0.0500

Open:0.0500

Low:0.0465

Close:0.0471

52wk High:0.1100

52wk Low:0.0150

Shares:441.58M

Float Shares:214.45M

Volume Ratio:0.10

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:-23.72%

ROA:-1.57%

PB:2.27

PE(LYR):- -

Loading ...

Overview Company News Filings

Oncotelic Therapeutics Issues 1.4 Million Warrants at $0.15 Exercise Price

Oncotelic Therapeutics Awards CEO Restricted Stock Tied to Capital Milestones

Oncotelic Therapeutics Inc - Amends Ica With Jefferson Capital Ventures, on December 31, 2025 - SEC Filing

THOMSON REUTERS

Oncotelic Therapeutics Inc - Amendment Modifies Milestone Threshold to $45 Mln - SEC Filing

THOMSON REUTERS

Oncotelic Therapeutics Raises Capital Through Private Placement of Convertible Notes and Warrants

Oncotelic Therapeutics Raises Funds Through Private Placement of Convertible Units

Oncotelic Therapeutics Launches AI Platform to Accelerate TGF-β Research

Oncotelic Therapeutics Identifies Context-Dependent Biomarkers in Liver and Pancreatic Cancer

Oncotelic Therapeutics Announces Private Placement of Convertible Notes and Warrants

Oncotelic and Sapu Nano Announces New Pk Data Demonstrating Iv Sapu003 Reduces Gi Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

THOMSON REUTERS

BRIEF-Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation

Oncotelic Therapeutics Inc. (Otcqb: Otlc) Emerging as Leader With New Independent Jv Valuation

THOMSON REUTERS

BRIEF-Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026

Oncotelic Therapeutics - Jv Is Preparing for a Potential Initial Public Offering on the Hong Kong Stock Exchange in Late 2026

THOMSON REUTERS

Top News Today: Stocks Mixed as AI Selloff Slows

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OTLC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OTLC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OTLC\",,,,,undefined,":{"symbol":"OTLC","market":"US","secType":"STK","nameCN":"Oncotelic Therapeutics, Inc.","latestPrice":0.0465,"timestamp":1771621200000,"preClose":0.04705,"halted":0,"volume":39914,"delay":15,"changeRate":-0.011689691817215768,"floatShares":214445090,"shares":441577283,"eps":0,"marketStatus":"Pre-Mkt","change":-0.00055,"latestTime":"02-20 16:00:00 EST Delay","open":0.05,"high":0.05,"low":0.0465,"amount":1921.4,"amplitude":0.074389,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771857000000},"marketStatusCode":1,"adr":0,"exchange":"OTCQB","adjPreClose":0.0465,"volumeRatio":0.09569412401434804},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OTLC\",,,,,undefined,":{"symbol":"OTLC","floatShares":214445090,"roa":"-1.57%","roe":"-23.72%","lyrEps":0,"volumeRatio":0.09569412401434804,"shares":441577283,"dividePrice":0,"high":0.05,"amplitude":0.074389,"preClose":0.04705,"low":0.0465,"week52Low":0.015,"pbRate":"2.27","week52High":0.11,"institutionHeld":0,"latestPrice":0.0465,"eps":0,"divideRate":0,"volume":39914,"delay":15,"open":0.05,"prevYearClose":0.0784,"prevWeekClose":0.0465,"prevMonthClose":0.0772,"prevQuarterClose":0.0784,"fiveDayClose":0.049,"twentyDayClose":0.0765,"sixtyDayClose":0.0935},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OTLC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-19","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731992400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-14","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-12","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1712894400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OTLC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OTLC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OTLC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607051616","title":"Oncotelic Therapeutics Issues 1.4 Million Warrants at $0.15 Exercise Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2607051616","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607051616?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:31","pubTimestamp":1769722304,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has issued 1,422,613 warrants to purchase shares of its common stock at an exercise price of $0.15 per share in connection with a Securities Purchase Agreement with Mast Hill Fund, LP. The warrants are part of a financing arrangement involving a convertible promissory note with a principal amount of $398,333.33. The shares of common stock issuable upon exercise of the warrants have not been registered under the Securities Act of 1933 and may only be offered or sold pursuant to an exemption from registration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieva","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL96f5qX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2606229898","title":"Oncotelic Therapeutics Awards CEO Restricted Stock Tied to Capital Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2606229898","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606229898?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:31","pubTimestamp":1769463102,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has entered into a new restricted stock agreement with CEO Dr. Vuong Trieu. Under the agreement, Dr. Trieu is eligible to receive up to 26,512 shares of convertible Series A Preferred Stock, which can be converted into up to 26,512,000 shares of common stock, based on the achievement of four specific performance milestones related to the company’s capital structure. The first milestone, involving the conversion of outstanding 2023 PPM Notes into new 2025 Units, has been achieved, granting Dr. Trieu 4,426 shares of Preferred Stock. Three additional milestones each allow for the vesting of 7,362 shares of Preferred Stock upon completion. The total potential issuance under the agreement represents approximately 4.99% of the company’s outstanding common stock as of the agreement date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL94Q0PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2601845675","title":"Oncotelic Therapeutics Inc - Amends Ica With Jefferson Capital Ventures, on December 31, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601845675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601845675?lang=en_us&edition=fundamental","pubTime":"2026-01-07 06:03","pubTimestamp":1767737002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70DN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLC"],"gpt_icon":0},{"id":"2601456798","title":"Oncotelic Therapeutics Inc - Amendment Modifies Milestone Threshold to $45 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601456798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601456798?lang=en_us&edition=fundamental","pubTime":"2026-01-07 06:03","pubTimestamp":1767737002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70DN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLC"],"gpt_icon":0},{"id":"2601117843","title":"Oncotelic Therapeutics Raises Capital Through Private Placement of Convertible Notes and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2601117843","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601117843?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:31","pubTimestamp":1767735098,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has completed the final tranche of its private placement, issuing a total of 44 units to 22 accredited investors. Each unit consists of a $25,000 note bearing 12% annual interest, convertible into either 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share. The units also include warrants to purchase Oncotelic or EdgePoint shares at set prices, with anti-dilution protections and a two-year exercise window. The offering was exempt from SEC registration under Rule 506 of Regulation D, and the company has granted registration rights for the shares issued in connection with this financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL5WzDv0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLC"],"gpt_icon":0},{"id":"2595100117","title":"Oncotelic Therapeutics Raises Funds Through Private Placement of Convertible Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2595100117","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595100117?lang=en_us&edition=fundamental","pubTime":"2025-12-31 06:01","pubTimestamp":1767132091,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has announced the completion of a private placement, entering into subscription agreements with 21 accredited investors for the sale of 32 units as part of an offering of up to 500 units. Each unit consists of a $25,000 note bearing 12% annual interest, convertible into either 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc., a subsidiary, at $1.00 per share. Additionally, each unit includes 250,000 warrants to purchase Oncotelic common stock at $0.12 per share or 25,000 warrants for EdgePoint stock at $1.25 per share, both with anti-dilution provisions and a two-year exercise period. The offering is exempt from SEC registration under Rule 506 of Regulation D.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL97sLl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLC"],"gpt_icon":0},{"id":"2593480859","title":"Oncotelic Therapeutics Launches AI Platform to Accelerate TGF-β Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480859?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:01","pubTimestamp":1766408485,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has announced the launch of PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful insights from large-scale biomedical datasets without the need to train bespoke large language models. Alongside this, the company has opened access to its comprehensive TGF-β literature corpus, which includes more than 125,000 PubMed abstracts, via a dedicated Discord research channel. The PDAOAI platform has already supported research published in peer-reviewed journals, such as the International Journal of Molecular Sciences, where it aided in synthesizing evidence on survival-associated biological axes, including TGFB2, DNMT3A, and GMPS, across various tumor microenvironment settings and patient populations. Researchers are invited to join the community for further collaboration and data exploration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL2PH0hl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","LU0314104364.USD","OTLC","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","NDAQ","SG9999014013.SGD","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2591647414","title":"Oncotelic Therapeutics Identifies Context-Dependent Biomarkers in Liver and Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647414","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647414?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:00","pubTimestamp":1765810845,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc., in collaboration with the Brush and Key Foundation, has announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences. The study, titled \"Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter,\" presents a comprehensive analysis of two emerging biomarkers-DNMT3A and GMPS-in hepatocellular carcinoma  and pancreatic ductal adenocarcinoma . The research, which analyzed data from over 7,000 patients, found that the prognostic significance of these biomarkers is highly context-dependent, influenced by immune composition, metabolic state, and innate immune pathways within the tumor microenvironment. These findings have already been published and highlight the importance of considering tumor context when interpreting biomarkers for cancer prognosis and therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1xT0dv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014021.USD","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4139","LU2210150020.SGD","OTLC","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590322507","title":"Oncotelic Therapeutics Announces Private Placement of Convertible Notes and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590322507","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590322507?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:02","pubTimestamp":1765317723,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has announced the completion of subscription agreements with certain accredited investors for a private placement, issuing a total of 11 units as part of an offering of up to 500 units. Each unit consists of a $25,000 note bearing 12% annual interest, convertible into either 250,000 shares of Oncotelic's common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc., a subsidiary, at $1.00 per share. The units also include warrants to purchase additional shares of Oncotelic or EdgePoint. The securities were sold in reliance on exemptions from registration under the Securities Act of 1933 and are not registered for public sale. Existing investors in a prior 2023 note offering were also able to exchange their notes for new units and convert EdgePoint shares into Oncotelic shares at a specified rate. The company also entered into a Registration Rights Agreement in connection with the offering.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL103P6n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLC"],"gpt_icon":0},{"id":"2588855044","title":"Oncotelic and Sapu Nano Announces New Pk Data Demonstrating Iv Sapu003 Reduces Gi Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588855044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588855044?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:00","pubTimestamp":1764770401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA8KWZWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2585146234","title":"BRIEF-Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2585146234","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585146234?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:15","pubTimestamp":1763734546,"startTime":"0","endTime":"0","summary":"BRIEF-Oncotelic Therapeutics Emerging As Leader With New Independent JV ValuationNov 21 (Reuters) - Oncotelic Therapeutics Inc OTLC.PK:ONCOTELIC THERAPEUTICS INC. (OTCQB: OTLC) EMERGING AS LEADER WITH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA9ZGF9H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2585145654","title":"Oncotelic Therapeutics Inc. (Otcqb: Otlc) Emerging as Leader With New Independent Jv Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145654","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145654?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:30","pubTimestamp":1763731800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA9ZGF9H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2584413454","title":"BRIEF-Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584413454","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584413454?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:13","pubTimestamp":1763644403,"startTime":"0","endTime":"0","summary":"BRIEF-Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026Oncotelic Therapeutics Inc OTLC.PK:ONCOTELIC THERAPEUTICS - JV IS PRE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW10I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2584316191","title":"Oncotelic Therapeutics - Jv Is Preparing for a Potential Initial Public Offering on the Hong Kong Stock Exchange in Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584316191","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584316191?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:56","pubTimestamp":1763643412,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW10I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2583682607","title":"Top News Today: Stocks Mixed as AI Selloff Slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682607?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:45","pubTimestamp":1763156700,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose amid doubts about the Federal Reserve's next move.COMMODITIES: Oil futures rose after Ukraine drone attacks on a Russian Black Sea port.Walmart picked one of its longtime executives, John Furner, to become its next chief executive, preserving its tradition of promoting an insider to steer the nation's biggest retailer. The 51-year-old Furner was seen inside the company as the likely heir apparent and ready for his next step after six years leading Walmart's U.S. business. Outside the company, the Walmart veteran-and son of a Walmart executive-was seen as a potential CEO candidate for other firms too.The reopened federal government will on Thursday release the first backlogged monthly jobs report, for the month of September. And a flood of other data is due to start flowing soon.They promised investments in the U.S. that would reduce Switzerland's trade imbalance with the U.S., according to people familiar wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","UAVS","IE00B2B36J28.USD","PNBK","LU0061474960.USD","SPRB","LITS","LU2468319806.SGD","BRC","SRG","BK4561","LU1066053197.SGD","MRK","PRPO","IIIV","LU2023250843.SGD","KALA","BK4152","LU2430703251.USD","BK4007","XP","NWBO","LU2750360641.GBP","STI","GPUS","LU2361044865.SGD","WMT","LWLG","LU1430594728.SGD","TORM","LU2430703178.SGD","RHEP","AAME","LU0861579265.USD","ALTS","ARMK","JJSF","TVGN","LU1974910355.USD","LU2592432038.USD","LFMD","ALBT","OTLC","BK4211","BYFC","HP","ASPI","LU0203347892.USD","IPAR"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}